Prescient Investment Analysis
Value, growth at reasonable price, long/short equity, bankruptcy situations

Oncothyreon Might Be Worth It

Oncothyreon, Inc. (ONTY) is a biotechnology company headquartered in Seattle, WA that is working on treatments for cancer. Its objectives are compassionate; however, a detached viewpoint is necessary to consider its worth for investors. It is not financially self-sustaining, and even though the stock is only priced at $1.77, it is particularly risky. The company's valuation is tied to its development of medical treatments, and though years of testing are required, the odds are against an individual product's approval for commercial use. However, it has several candidates, which increases the probability of one getting through. Further, for those who are willing to write options, costs of being a shareholder may be substantially lowered.

Oncothyreon's web site includes a graphical description...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details